Celldex Therapeutics, Inc.

Contributing Author

Recent Articles by Celldex Therapeutics, Inc.

Sep-17	Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025 CLDX GlobeNewswire
Sep-09	Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference CLDX GlobeNewswire
Aug-19	Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE) CLDX GlobeNewswire
Aug-07	Celldex Reports Second Quarter 2025 Financial Results and Provides Corporate Update CLDX GlobeNewswire
Jun-14	Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025 CLDX GlobeNewswire
Jun-12	Celldex Presents Unprecedented 76 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI Congress 2025 CLDX GlobeNewswire
Jun-10	Celldex Announces Upcoming Presentations of Barzolvolimab Phase 2 Data in Chronic Spontaneous Urticaria at EAACI 2025 Congress CLDX GlobeNewswire
Jun-06	Celldex Therapeutics Announces Election of Denice Torres to its Board of Directors CLDX GlobeNewswire
May-08	Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update CLDX GlobeNewswire
May-05	Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease CLDX GlobeNewswire